Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
The standard adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer is 5 years of tamoxifen, but recurrences and side-effects restrict its… Expand
Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma
The goal of the current study was to compare the long‐term (25‐month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or… Expand
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
BACKGROUND
Little data exist on whether efficacy benefits or side-effects persist after 5 years of adjuvant treatment with an aromatase inhibitor. We aimed to study long-term outcomes in the… Expand
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health…
- J. Cuzick, M. Dowsett, +10 authors J. Forbes
- Medicine
- Journal of clinical oncology : official journal…
- 10 November 2011
PURPOSE
We recently reported that the mRNA-based, 21-gene Genomic Health recurrence score (GHI-RS) provided additional prognostic information regarding distant recurrence beyond that obtained from… Expand
The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women.
- M. Harvie, C. Wright, +13 authors A. Howell
- Chemistry, Medicine
- The British journal of nutrition
- 28 October 2013
Intermittent energy restriction may result in greater improvements in insulin sensitivity and weight control than daily energy restriction (DER). We tested two intermittent energy and carbohydrate… Expand
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
- A. Howell, J. Robertson, +7 authors C. Morris
- Medicine
- Journal of clinical oncology : official journal…
- 15 August 2002
PURPOSE
To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) and anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.… Expand
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
- J. Cuzick, J. Forbes, +4 authors A. Howell
- Medicine
- Journal of the National Cancer Institute
- 21 February 2007
BACKGROUND
Initial results from the first International Breast Cancer Intervention Study (IBIS-I) found that tamoxifen reduced the risk of invasive estrogen receptor (ER)-positive tumors by 31% in… Expand
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a…
- M. Dowsett, J. Cuzick, +11 authors S. Shak
- Medicine
- Journal of clinical oncology : official journal…
- 10 April 2010
PURPOSE To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in the tamoxifen and anastrozole arms of the Arimidex, Tamoxifen, Alone or… Expand
Autophagy in cancer associated fibroblasts promotes tumor cell survival
- Ubaldo e. Martinez-outschoorn, C. Trimmer, +14 authors F. Sotgia
- Biology, Medicine
- Cell cycle
- 1 September 2010
Recently, using a co-culture system, we demonstrated that MCF7 epithelial cancer cells induce oxidative stress in adjacent cancer-associated fibroblasts, resulting in the autophagic/lysosomal… Expand
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized…
- A. Howell, J. Robertson, +8 authors C. Osborne
- Medicine
- Journal of clinical oncology : official journal…
- 1 May 2004
PURPOSE
To evaluate the efficacy and tolerability of fulvestrant (Faslodex; AstraZeneca Pharmaceuticals LP, Wilmington, DE), a new estrogen receptor (ER) antagonist that downregulates ER and has no… Expand